BiotechTube

Rescue Intravitreal Aflibercept Injection

ApprovedUNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 39/100
39
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
✓
Phase 3
5
Approved
Indication / Disease

Neovascular Polypoidal Choroidal Vasculopathy

Conditions

Neovascular Polypoidal Choroidal Vasculopathy

Trial Timeline

Mar 1, 2014 → Mar 1, 2016

NCT ID
NCT02092532

About Rescue Intravitreal Aflibercept Injection

Rescue Intravitreal Aflibercept Injection is a approved stage product being developed by Regeneron Pharmaceuticals for Neovascular Polypoidal Choroidal Vasculopathy. The current trial status is unknown. This product is registered under clinical trial identifier NCT02092532. Target conditions include Neovascular Polypoidal Choroidal Vasculopathy.

What happened to similar drugs?

17 of 20 similar drugs in Neovascular Polypoidal Choroidal Vasculopathy were approved

Approved (17) Terminated (3) Active (3)
✅ranibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅Intraviteal Ranibizumab 0.5mgNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅RanibizumabNovartisApproved
✅BrolucizumabNovartisApproved

Hype Score Breakdown

Clinical
20
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02092532ApprovedUNKNOWN

Competing Products

20 competing products in Neovascular Polypoidal Choroidal Vasculopathy

See all competitors
ProductCompanyStageHype Score
CLS-AX + Anti-VEGFClearside BiomedicalPhase 1/2
22
CLS-AX + AfliberceptClearside BiomedicalPhase 2
25
Eylea + ALT-L9AlteogenPhase 1
29
UBX1325 injection 50 μL + EYLEA® (aflibercept) Injection 2 mg (0.05mL)Unity BiotechnologyPhase 2
25
DS-7080a + RanibizumabDaiichi SankyoPhase 1
29
Avacincaptad PegolAstellas PharmaPhase 1
29
Avacincaptad Pegol + Avastin + Lucentis + EyleaAstellas PharmaPhase 2
27
Avacincaptad Pegol + LucentisAstellas PharmaPhase 2
35
KHK4951 + Aflibercept InjectionKyowa KirinPhase 2
39
Surabgene Lomparvovec (ABBV-RGX-314) + Ranibizumab ControlAbbViePhase 3
47
Ranibizumab + Local Steroid + Topical SteroidAbbViePhase 2
39
LucentisNovartisPre-clinical
26
ranibizumabNovartisPhase 3
40
BrolucizumabNovartisPre-clinical
18
ranibizumabNovartisApproved
43
brolucizumab + ranibizumab + afliberceptNovartisPre-clinical
26
BeovuNovartisPre-clinical
26
RanibizumabNovartisPhase 3
40
RanibizumabNovartisApproved
43
Intraviteal Ranibizumab 0.5mgNovartisApproved
43